Prostatype Genomics

Prostatype Genomics is a commercial-stage diagnostics company addressing the critical unmet need for accurate risk stratification in prostate cancer. Its core achievement is the development and commercialization of the Prostatype® test, a validated prognostic tool that integrates a proprietary 3-gene signature with standard clinical parameters to predict prostate cancer-specific mortality. The company's strategy is to drive clinical adoption in Europe and secure regulatory clearance and reimbursement in the massive US market, leveraging a seasoned management team with deep diagnostics and urology expertise. Prostatype aims to become a standard-of-care tool to personalize treatment, improve patient outcomes, and generate cost savings for healthcare systems.

RNA-based gene expression test measuring three embryonic stem cell genes in FFPE prostate biopsy tissue, integrated with clinical parameters (PSA, Gleason, Stage) via a proprietary algorithm to generate a prognostic P-score for prostate cancer-specific mortality.